Sugi Predict

Sugi Predict / Compounds / SCHEMBL1899136

SCHEMBL1899136

SCHEMBL1899136

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1C(O)C[C@@H]2O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHBG P04278 7/20 0.71
▸ LMNA P02545 7/20 0.69
▸ SERPINA6 P08185 6/20 0.69
▸ HSD17B10 Q99714 5/20 0.69
▸ CYP3A4 P08684 5/20 0.69
▸ TSHR P16473 5/20 0.69
▸ CYP19A1 P11511 5/20 0.69
▸ MAPK1 P28482 5/20 0.69
▸ SNCA P37840 4/20 0.69
▸ NR3C1 P04150 4/20 0.69
▸ PGR P06401 4/20 0.69
▸ MAPT P10636 4/20 0.69
▸ AR P10275 3/20 0.69
▸ GPBAR1 Q8TDU6 3/20 0.69
▸ SIGMAR1 Q99720 3/20 0.69
▸ CACNA1C Q13936 2/20 0.69
▸ CYP51A1 Q16850 2/20 0.69
▸ OR51E2 Q9H255 1/20 0.69
▸ SMN1; SMN2 Q16637 5/20 0.58
▸ ALDH1A1 P00352 5/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23711138 1.00 SHBG (0.71) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL13752813 1.00 SHBG (0.71) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL1899132 1.00 SHBG (0.71) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL1901199 1.00 SHBG (0.71) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL4104457 1.00 SHBG (0.71) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL8647891 0.89 SHBG (0.67) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL8647886 0.89 SHBG (0.67) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL23723902 0.86 CYP19A1 (0.61) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL23711106 0.86 CYP19A1 (0.61) SHBGLMNASERPINA6HSD17B10CYP3A4
SCHEMBL6323169 0.86 CYP3A4 (0.69) SHBGLMNASERPINA6HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943602-B2 Pharmaceutical application of 15- or 16-substituted testosterone analogues PANTARHEI BIOSCIENCE B.V. (NL) 2011-05-17 — — US claimed
EP-1551415-B1 ORAL PHARMACEUTICAL COMPOSITION COMPRISING 15-HYDROXYTESTOSTERONE AND ITS ANALOGUES PANTARHEI BIOSCIENCE BV (NL) 2009-12-23 — — EP claimed
US-20060122158-A1 Pharmaceutical application of 15- or 16-substituted testosterone analogues WILMINGTON TRUST 2006-06-08 — — US claimed
CN-1694710-A Pharmaceutical use of 15-or 16-substituted testosterone analogues PANTARHEI BIOSCIENCE BV (NL) 2005-11-09 — — CN claimed
EP-1551415-A1 PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES Pantarhei Bioscience B.V. (NL) 2005-07-13 — — EP claimed
WO-2004022065-A1 PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES PANTARHEI BIOSCIENCE B.V. (NL) 2004-03-18 — — WO claimed
CN-101785775-B Pharmaceutical application of 15- or 16- substituted testosterone analogues PANTARHEI BIOSCIENCE BV 2015-03-25 — — CN disclosed
CN-101785775-B Pharmaceutical application of 15- or 16- substituted testosterone analogues PANTARHEI BIOSCIENCE BV 2015-03-25 — — CN disclosed
CN-1694710-B Pharmaceutical use of 15-or 16-substituted testosterone analogues PANTARHEI BIOSCIENCE BV 2012-09-05 — — CN disclosed
CN-1694710-B Pharmaceutical use of 15-or 16-substituted testosterone analogues PANTARHEI BIOSCIENCE BV 2012-09-05 — — CN disclosed
US-7943602-B2 Pharmaceutical application of 15- or 16-substituted testosterone analogues PANTARHEI BIOSCIENCE B.V. (NL) 2011-05-17 — — US disclosed
US-7943602-B2 Pharmaceutical application of 15- or 16-substituted testosterone analogues PANTARHEI BIOSCIENCE B.V. (NL) 2011-05-17 — — US disclosed
CN-101785775-A Pharmaceutical application of 15- or 16- substituted testosterone analogues PANTARHEI BIOSCIENCE BV 2010-07-28 — — CN disclosed
EP-1551415-A1 PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES Pantarhei Bioscience B.V. (NL) 2005-07-13 — — EP disclosed
EP-1551415-A1 PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES Pantarhei Bioscience B.V. (NL) 2005-07-13 — — EP disclosed
US-6881729-B2 Bile compound and method of controlling behavior of lampreys therewith BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2005-04-19 — — US disclosed
WO-2004022065-A1 PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES PANTARHEI BIOSCIENCE B.V. (NL) 2004-03-18 — — WO disclosed
WO-2004022065-A1 PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES PANTARHEI BIOSCIENCE B.V. (NL) 2004-03-18 — — WO disclosed
US-20030108583-A1 Bile compound and method of controlling behavior of lampreys therewith BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2003-06-12 — — US disclosed
US-6174684-B1 NUCLEOTIDE SEQUENCES CODING PROTEINS ASSOCIATED METABOLISM OF COMPOUNDS; FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER; ANTICARCINOGENIC AGENTS TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2001-01-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108583-A1 Bile compound and method of controlling behavior of lampreys therewith NR1H4, CYP46A1, GPBAR1 SHBG 243/4885LMNA 3655/4885SERPINA6 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.